Paul Herrling

First Person | Paul Herrling Courtesy of Ruder Finn When Paul Herrling didn't do his homework at his Swiss boarding school, the facility's science-loving director devised unusual punishments. The then-teenaged Herrling, now Novartis' head of corporate research, had to catalog the man's collection of crickets, which the director had recovered from ice, ages old, on a nearby Italian mountain. "He was studying glacial repopulation," says Herrling. The discipline, and the fervor of the direct

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

When Paul Herrling didn't do his homework at his Swiss boarding school, the facility's science-loving director devised unusual punishments. The then-teenaged Herrling, now Novartis' head of corporate research, had to catalog the man's collection of crickets, which the director had recovered from ice, ages old, on a nearby Italian mountain. "He was studying glacial repopulation," says Herrling.

The discipline, and the fervor of the director's science lectures, opened Herrling's eyes to biology. "With every lesson, I was learning absolutely astonishing stuff," he explains.

Herrling was hired in 1975 when the Swiss government, he says, was telling drug houses to hire their own instead of the better-trained English scientists. Multilingual and well traveled, Herrling visits Singapore six times a year, where he directs the newly established Novartis Institute for Tropical Diseases. He spent his youth in Alexandria, Egypt.

He makes the most of his time on the road. An accomplished antiquarian, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies